Harvinder Virk

Harvinder Virk

Auto-generated profile, based on publicly available information

Harvinder Virk

NIHR Respiratory Biomedical Research Centre, Department of Respiratory Sciences, University of Leicester

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2008 in SLEEP
Verified
Journal Article
Open access
PDF file
AHAllison G. Harvey
Allison G. Harvey
KSKathleen Stinson
Kathleen Stinson
KWKatriina L. Whitaker
Katriina L. Whitaker
DMDamian Moskovitz
Damian Moskovitz
HVHarvinder Virk
Harvinder Virk
“Sleep quality” is poorly defined yet ubiquitously used by researchers, clinicians and patients. While poor sleep quality is a key feature of insomnia, there are few empirical investigations of sleep quality in insomnia patients. Accordingly, our aim was to investigate the subjective meaning of sleep quality among individuals with insomnia and normal sleepers. Cross sectional between groups (insomnia vs. good sleeper). Analyses were conducted across three outcome variables: (1) a “Speak Freely” procedure in which participants' descriptions of good and poor sleep quality nights were analysed, (2) a "Sleep Quality Interview" in which participants judged the relative importance of variables included in previous research on sleep quality and (3) a sleep quality diary completed over seven consecutive nights. University Department of Psychiatry Individuals with insomnia (n = 25) and normal sleepers (n = 28). N/A Both the insomnia and normal sleeper groups defined sleep quality by tiredness on waking and throughout the day, feeling rested and restored on waking, and the number of awakenings they experienced in the night. The insomnia group had more requirements for judging sleep to be of good quality. The meaning of sleep quality among individuals with insomnia and normal sleepers was broadly similar. A comprehensive assessment of a patient's appraisal of their sleep quality may require an assessment of waking and daytime variables.

16 October 2023 in F1000Research
Verified
Journal Article
Open access
PDF file
MBMichael S. Biddle
Michael S. Biddle
HVHarvinder S. Virk
Harvinder S. Virk
YCharOS is a collaborative initiative aimed at characterising antibodies against the entire human proteome. As of August 2023, they have presented comprehensive knockout characterisation data for 812 antibodies and 78 proteins using techniques such as Western blot, immunoprecipitation, and immunofluorescence. YCharOS consolidates its data into reports (one protein per report) available on Zenodo, a public repository controlled by CERN, to ensure open access. To enhance the visibility of their work, the group is progressively converting their Zenodo reports into F1000 articles, collected on the YCharOS Gateway, and indexed via PubMed. Their data is also accessible through searches on the Antibody Registry. The provided data is a valuable resource for researchers when selecting antibodies for specific applications, although certain limitations should be considered. The data accumulated thus far has illuminated the extent of the problem when poorly performing antibodies are employed in research. While the scientific community was already aware that this was likely a widespread issue, the establishment of a collaborative open science project with industry partners introduces an innovative solution that holds the potential to yield significant returns on investment in the public interest. This potential is substantiated by the number of antibodies that have either been withdrawn or had their recommended usage altered by the vendor. However, despite the discovery of high-performing renewable antibodies for most of the studied proteins, this accounts for a tiny fraction of the human proteome and the commercial antibody market. To realise the full potential of this work, end-users must adjust their antibody procurement and usage practises in line with the provided data. This editorial offers a guide on how individual scientists can utilise the YCharOS data, in addition to sharing the insights gained from the data thus far with the wider scientific community.

1 August 2016 in Translational Research
Verified
Journal Article
Closed access
HVHarvinder Virk
Harvinder Virk
GAGreer Arthur
Greer Arthur
PBPeter Bradding
Peter Bradding

23 November 2023 in eLife
Verified
Journal Article
Open access
RARiham Ayoubi
Riham Ayoubi
JRJoel Ryan
Joel Ryan
MBMichael S Biddle
Michael S Biddle
WAWalaa Alshafie
Walaa Alshafie
MFMaryam Fotouhi
Maryam Fotouhi
CLCarl Laflamme
Carl Laflamme
Antibodies are critical reagents to detect and characterize proteins. It is commonly understood that many commercial antibodies do not recognize their intended targets, but information on the scope of the problem remains largely anecdotal, and as such, feasibility of the goal of at least one potent and specific antibody targeting each protein in a proteome cannot be assessed. Focusing on antibodies for human proteins, we have scaled a standardized characterization approach using parental and knockout cell lines (Laflamme et al., 2019) to assess the performance of 614 commercial antibodies for 65 neuroscience-related proteins. Side-by-side comparisons of all antibodies against each target, obtained from multiple commercial partners, have demonstrated that: (i) more than 50% of all antibodies failed in one or more applications, (ii) yet, ~50–75% of the protein set was covered by at least one high-performing antibody, depending on application, suggesting that coverage of human proteins by commercial antibodies is significant; and (iii) recombinant antibodies performed better than monoclonal or polyclonal antibodies. The hundreds of underperforming antibodies identified in this study were found to have been used in a large number of published articles, which should raise alarm. Encouragingly, more than half of the underperforming commercial antibodies were reassessed by the manufacturers, and many had alterations to their recommended usage or were removed from the market. This first study helps demonstrate the scale of the antibody specificity problem but also suggests an efficient strategy toward achieving coverage of the human proteome; mine the existing commercial antibody repertoire, and use the data to focus new renewable antibody generation efforts.

6 December 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HVH. S. Virk
H. S. Virk
MRM. Z. Rekas
M. Z. Rekas
MBM. S. Biddle
M. S. Biddle
AWA. K. A. Wright
A. K. A. Wright
JSJ. Sousa
J. Sousa
PBP. Bradding
P. Bradding
The transient receptor potential cation channel family member ankyrin 1 (TRPA1) is a potential target for several diseases, but detection of human TRPA1 (hTRPA1) protein in cells and tissues is problematic as rigorous antibody validation is lacking. We expressed hTRPA1 in a TRPA1-negative cell line to evaluate 5 commercially available antibodies by western blotting, immunofluorescence, immunocytochemistry and flow cytometry. The three most cited anti-TRPA1 antibodies lacked sensitivity and/or specificity, but two mouse monoclonal anti-TRPA1 antibodies detected hTRPA1 specifically in the above assays. This enabled the development of a flow cytometry assay, which demonstrated strong expression of TRPA1 in human lung myofibroblasts, human airway smooth muscle cells but not lung mast cells. The most cited anti-TRPA1 antibodies lack sensitivity and/or specificity for hTRPA1. We have identified two anti-TRPA1 antibodies which detect hTRPA1 specifically. Previously published data regarding human TRPA1 protein expression may need revisiting.

14 August 2024 in eLife
Verified
Journal Article
Open access
RKRichard A Kahn
Richard A Kahn
HVHarvinder Virk
Harvinder Virk
CLCarl Laflamme
Carl Laflamme
DHDouglas W Houston
Douglas W Houston
NPNicole K Polinski
Nicole K Polinski
SLSkye Longworth
Skye Longworth
Antibodies are used in many areas of biomedical and clinical research, but many of these antibodies have not been adequately characterized, which casts doubt on the results reported in many scientific papers. This problem is compounded by a lack of suitable control experiments in many studies. In this article we review the history of the ‘antibody characterization crisis’, and we document efforts and initiatives to address the problem, notably for antibodies that target human proteins. We also present recommendations for a range of stakeholders – researchers, universities, journals, antibody vendors and repositories, scientific societies and funders – to increase the reproducibility of studies that rely on antibodies.